Ann: Trading Halt, page-37

Guessing KZA may have done a deal with Memorial Sloan Kettering.... for licensing  a drug that hospital has been developing, in a 2 drug combination for Ferroptosis. (If I am totally off the mark.....then this  current info may still be of interest.)

Associated with the license, would be some form of partnership with MSK (which is the case anyway with a typical drug license)

MSK, year on year are consistently rated No1 or 2 best hospital in the world.

MSK are very familiar with Kazia,s  paxalisib ...already conducting a trial and a Prof Ingo Melinghoff from MSK is the lead investigation in the pax arm of the GBM Agile trial.

Ramifications of such an arrangement  - would be first real endorsement that pax works outside the brain - may make it hard for other PI3K Inhibitors (many already in trials) to compete and certainly preempt positive results in the current KZA clinical trials, of which MSK are heavily involved.

MSK are currently conducting hundreds of other cancer clinical trails - they would be keen to get the ball rolling with pax - and the drug they have developed. So maybe an announcement also of another clinical trial .  Mesothelioma another big guess - but at least here is some backup to guessing.

----------------------------------
Trait Found in Mesothelioma May Present Significant Target for New Cancer Treatment
Published on December 02, 2020
Though malignant mesothelioma is a uniquely challenging form of cancer, it shares many traits with other cancers that scientists are investigating as therapeutic targets. Among these is a mutation of PI3K-AKT-mTOR, a pathway that controls metabolism. When this mutation is present it protects cancerous cells, but researchers from Memorial Sloan Kettering Cancer Center in New York believe they’ve found a way to block this effect, creating a potent and effective way of killing cancerous tumors.

Sabotaging Mutation May Present Key to Mesothelioma Tumor Death

The new research is focused on ferroptosis, a type of cell death triggered by oxidative stress that mesothelioma and other types of cancers appear immune to. Normally, free radicals and chemicals accumulate in cells as they use oxygen to burn fuel for energy, and these byproducts – including iron — end up killing the cell. But mutations in the PI3K-AKT-mTOR pathway protect against this stress.



---------------------------------------------------------------------------------------------

More evidence that cellular 'death by iron' could be promising avenue of cancer treatment -- ScienceDaily


A Commonly Mutated Pathway
The particular mutations Dr. Jiang and colleagues studied affect a signal-sending pathway called PI3K-AKT-mTOR, which controls metabolism. Mutations in this pathway are among the most common found in cancer. That likely reflects the fact that cancer cells have increased metabolic demands owing to how quickly they reproduce. Cancers with mutations in the PI3K-AKT-mTOR pathway are some of the most difficult to treat.

The team found that tumor cells with these mutations demonstrated a hardy resistance to an experimental ferroptosis-inducing drug that was administered to cells growing in a dish. When the scientists added drugs that block the action of this metabolic pathway to the ferroptosis-inducing drug, the cancer cells died.